- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 78
- States / cities
- Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 1,771
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Cancer, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
- Interventions
- NGM438, Pembrolizumab (KEYTRUDA ®)
- Drug
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Denver, Colorado • New Haven, Connecticut • Detroit, Michigan + 3 more
- Conditions
- Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), EGFR Activating Mutation, EGFR Mutation-Related Tumors
- Interventions
- BG-60366
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- Naporafenib, Trametinib
- Drug
- Lead sponsor
- Erasca, Inc.
- Industry
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- San Francisco, California • New Haven, Connecticut • Sarasota, Florida + 10 more
- Conditions
- Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
- Interventions
- inupadenant, Placebo, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- iTeos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Fayetteville, Arkansas • Tampa, Florida
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- PD0332991
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Tampa, Florida
- Conditions
- Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Interventions
- SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Westwood, Kansas
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- erlotinib hydrochloride, celecoxib, placebo, laboratory biomarker analysis, immunohistochemistry staining method, fluorescence in situ hybridization, mutation analysis, protein expression analysis, gene expression analysis
- Drug · Other · Genetic
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 2
- States / cities
- Duarte, California • South Pasadena, California
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
- Interventions
- amifostine trihydrate, carboplatin, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2004
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- REGN4659, Cemiplimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Grand Rapids, Michigan • Charlotte, North Carolina + 3 more
- Conditions
- Mesothelin Positive, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Interventions
- Anetumab Ravtansine, Atezolizumab, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Medical Device Usage and Evaluation, Physical Performance Testing, Positron Emission Tomography, Survey Administration
- Procedure · Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 225
- States / cities
- Fort Smith, Arkansas • Aurora, Colorado • Boulder, Colorado + 160 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Carboplatin, Paclitaxel, Ramucirumab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- CBT-1, Placebo
- Drug · Other
- Lead sponsor
- CBA Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 1
- States / cities
- Tuscon, Arizona
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell), Pancreas Cancer, Duct Cell Adenocarcinoma
- Interventions
- ADC
- Drug
- Lead sponsor
- MBrace Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- San Francisco, California • Grand Rapids, Michigan • East Brunswick, New Jersey + 4 more
- Conditions
- Advanced NSCLC, Metastatic Lung Cancer
- Interventions
- Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed, Cisplatin/Carboplatin
- Drug · Combination Product
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 59
- States / cities
- Fountain Valley, California • Fullerton, California • San Francisco, California + 45 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- ASA404, Placebo, docetaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 88
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Bentonville, Arkansas + 76 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- canakinumab, canakinumab-matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 4
- States / cities
- Long Beach, California • Los Angeles, California • Orlando, Florida + 1 more
- Conditions
- Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma, Lung Neoplasms
- Interventions
- Drug: Hyperacute Lung Cancer Cell Vaccine
- Biological
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Navitoclax, Osimertinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 18
- States / cities
- Sacramento, California • Aurora, Colorado • Tampa, Florida + 11 more
- Conditions
- Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer
- Interventions
- aldesleukin, mutant p53 peptide pulsed dendritic cell vaccine, ras peptide cancer vaccine, sargramostim, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- RAD001, erlotinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 4 more
- Conditions
- Lung Cancer
- Interventions
- oxaliplatin, paclitaxel
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 11
- States / cities
- Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more
- Conditions
- Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer
- Interventions
- NC762
- Drug
- Lead sponsor
- NextCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Hackensack, New Jersey + 5 more